AuraSense forms advisory board
This article was originally published in Scrip
Executive Summary
AuraSense, a US biotechnology company founded in February 2009 to pursue the therapeutic potential of engineered nanoparticles, has formed an advisory board. The five members are: Mark Booth, chief commercial officer at Orexigen Therapeutics; Dr William O'Neill, executive dean for clinical affairs at Miller School of Medicine, University of Miami; Dr Bertram Pitt, professor of medicine emeritus, University of Michigan School of Medicine; Dr Steven Rosen, Genevieve Teuton professor of medicine, Feinberg School of Medicine, Northwestern University; and Dr Erik Sontheimer, associate professor, department of biochemistry, molecular biology and cell biology, Northwestern University.